MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST002124/mwtabprimaryOK200MetabolomicsEIMass SpectrometryMus Musculushttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST002124Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D).Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D).Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D).Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D).Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D).Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C).Bone MarrowSun Yat-sen UniversityGC POSITIVE ION MODE.MetabolomicsWorkbenchProline, 2TBDMSTyrosine, 3TBDMS[13C, 15N]Tyrosine, 3TBDMSIsoleucine, 2TBDMSCitrate[13C]Fumatate[13C, 15N]Glutamic acid, 3TBDMSAlanine, 2TBDMSL-Cysteine, 3TBDMS[13C]Alpha_Ketoglutarate[13C, 15N]Methionine, 2TBDMS[13C, 15N]Isoleucine, 2TBDMS[13C, 15N]Histidine, 3TBDMSGlycine, 2TBDMS[13C, 15N]Valine, 2TBDMS[13C, 15N]Phenylalanine, 2TBDMS[13C, 15N]Glycine, 2TBDMS[13C, 15N]Lysine, 3TBDMSThreonine, 3TBDMSAspartic acid, 3TBDMSAlpha_Ketoglutarate[13C, 15N]Leucine, 2TBDMSHydroxyproline, (E)-, 3TBDMSSuccinateMethionine, 2TBDMSHistidine, 3TBDMS[13C, 15N]Serine, 3TBDMS[13C]Malate[13C, 15N]Alanine, 2TBDMS[13C, 15N]Aspartic acid, 3TBDMSPhenylalanine, 2TBDMSSerine, 3TBDMS[13C]SuccinateMalateGlutamic acid, 3TBDMSLeucine, 2TBDMSLysine, 3TBDMSFumatate[13C, 15N]Threonine, 3TBDMS[13C]CitrateValine, 2TBDMS[13C, 15N]Proline, 2TBDMSGlutamine, 3TBDMSAmino Acid, Acid, amino acids, Amino acids, Aminokarbonsaeure, Aminosaeure, Aminocarbonsaeure, Amino acid, Cell., Acids, alpha-amino acids, alpha-amino acid, Amino, alpha-amino carboxylic acidsiones., Ionen, ion, Ion, ionsfalseAmino acids and TCA substrates in hematopoietic cells (Part1)ST00212410090